National Medicines Symposium 2024 speakers (L to R): Steve Waller, Professor Jennifer Martin, Professor Libby Roughead, Tegan Taylor[/caption]
This CPD activity is sponsored by Reckitt. All content is the true, accurate and independent opinion of the speakers and the views expressed are entirely their own.[/caption]
References
- Khanna S, Shaw L, Hyman MJ, et al. Association of metformin use with risk of newly onset neovascular age-related macular degeneration development. Retina 2024;44(2):205–13.
- Macular Disease Foundation Australia. About age-related macular degeneration Sydney (NSW): Macular Disease Foundation Australia,; n.d. At: mdfoundation.com.au/about-macular-disease/age-related-macular-degeneration/amd-overview/
- National Eye Institute. Age-related macular degeneration (AMD) Bethesda (MD): National Eye Institute,; 2021. At: nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration#:~:text=Age%2Drelated%20macular%20degeneration%20(AMD)%20is%20an%20eye%20disease,the%20back%20of%20the%20eye)
- Macular Disease Foundation Australia. Treatment for age-related macular degeneration Sydney (NSW): Macular Disease Foundation Australia,; n.d. At: mdfoundation.com.au/about-macular-disease/age-related-macular-degeneration/amd-treatment/#:~:text=Anti%2DVEGF%20medication%20can%20block,the%20vitreous)%20inside%20the%20eye
- Australian Medicines Handbook. Australian Medicines Handbook – Rifaximin: Australian Medicines Handbook Pty Ltd; 2023.
- Waldenlind K, Delcoigne B, Saevarsdottir S, et al. Disease-modifying antirheumatic drugs and risk of thyroxine-treated autoimmune thyroid disease in patients with rheumatoid arthritis. J Intern Med 2024;295(3):313–21.
